Ischemia Care

Executive Summary

Ischemia Care is a San Francisco-based diagnostics company developing ISCDx, a blood test that uses RNA expression analysis to differentiate between cardioembolic and large artery atherosclerosis causes of stroke. This CLIA-validated laboratory-developed test aims to improve diagnostic accuracy, reduce hospital costs, and guide treatment decisions. The company targets the significant unmet need in stroke etiology classification, which currently relies on expensive and time-consuming imaging. While ISCDx is already commercially available as an LDT, broader adoption hinges on securing FDA clearance and generating robust clinical evidence. With a strong IP position and a clear value proposition, Ischemia Care is well-positioned in the precision diagnostics space, though it faces competition from established players and must navigate regulatory and reimbursement hurdles.

Upcoming Catalysts (preview)

• Q3 2026Publication of pivotal clinical validation study in a peer-reviewed journal70% success
• Q1 2027FDA 510(k) clearance or breakthrough device designation40% success
• Q4 2026Strategic partnership or licensing agreement with a major diagnostics or pharmaceutical company30% success